Serplulimab  (Synonyms: HLX 10)

Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

Serplulimab (10 μg/mL; 0-16 h) can increase the phosphorylation levels of AKT1/2/3 (T308), AKT1/2/3 (S473), and STAT3 (Y705) in Jurkat-PD-1 cells in response to PD-1 signaling blockade^[1].
Serplulimab (0-1000 ng/mL; 2 days) can enhance the production of IFNγ in T cells, increase the cytotoxicity against SGC7901, and reverse the inhibitory effect of SGC7901 on T-cell effector functions in the co-culture system of CD8⁺ T cells and SGC7901 gastric cancer cells. The effect is even better when combined with HLX53^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Serplulimab (intraperitoneal injection; twice a week; until the end of the experiment) has anti-tumor activity in mice, and the effect is better when combined with HLX53^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

144.18 kDa

2231029-82-4

Liquid

Colorless to light yellow

[Serplulimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Zhang Y, et al. Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. MAbs. 2024 Jan-Dec;16(1):2419838.  [Content Brief]

  [2]. Lee A. Serplulimab: First Approval. Drugs. 2022 Jul;82(10):1137-1141.  [Content Brief]